Midomafetamine

ANC raids led to drug seizures worth Rs 9.2 lakh, arrests, and a breakthrough in an interstate ganja network. Detainees at Sunburn EDM tested positive for drugs; some released. Separate operations arrested individuals for possessing Ecstasy, Charas, and cocaine. ANC cracked a ganja smuggling ring, arresting its leader with inter-state police support.

Goa's Anti-Narcotics Cell (ANC) conducted raids, arresting individuals and seizing drugs worth Rs 9.2 lakh, dismantling an interstate ganja network. Arrests included festival-goers, a local youth, a Nigerian national, and a ganja network kingpin, showcasing effective inter-state coordination.

Colorado legalizes psychedelic therapy, facing opposition in Colorado Springs. Veterans advocate for psilocybin to treat PTSD, despite city council restrictions. Psilocybin therapy, legal in Colorado and Oregon, remains federally illegal and under strict regulation.

Psychedelics, once sidelined, are now being reintroduced as therapies for severe psychiatric disorders. Despite approvals in countries like France, the US, and Australia, scientific evidence supporting their effectiveness is weak, with significant risks and challenges in clinical trials. Experts call for stricter regulation and improved trial protocols to ensure safety and efficacy.

Substance use disorders (SUDs) are a global issue, with research in 2024 highlighting key findings: a rise in drug overdose deaths, primarily from synthetic opioids; the ineffectiveness of certain interventions in reducing opioid deaths; neurological impacts of non-fatal overdoses; potential of psychedelics like ibogaine for treating PTSD and addictions; cannabis use's negative impact on academic achievement; prevalence of polysubstance use; advances in understanding behavioral addictions; genetic links between cannabis use and other SUDs; therapeutic effects of psilocybin on brain connectivity; and parallels between food and drug addiction mechanisms.

Ryan Chrapko transformed his life using psilocybin, moving from substance abuse to mental health improvement. Colorado's Proposition 122 now allows clinical psychedelic use, offering therapeutic benefits for conditions like PTSD and depression, with professional guidance enhancing outcomes.

The FDA rejected Lykos Therapeutics' application for MDMA-assisted PTSD therapy, citing insufficient evidence and flawed study design. This decision impacts MAPS, founded by Rick Doblin, and the future of psychedelic treatment research.

Psychedelics like esketamine, psilocybin, and MDMA are being reconsidered for treating severe psychiatric disorders, despite weak scientific evidence and significant risks. Challenges in clinical trials and accelerated approvals raise concerns about efficacy and safety. Experts call for stricter regulation and improved trial protocols to ensure patient safety.

References cover cathinone derivatives, synthetic cathinones, new psychoactive substances, and their pharmacology, toxicology, and effects on users.

2024 saw significant mental health advances: FDA approved Rejoyn, a digital therapeutic for depression, and Cobenfy, a new schizophrenia drug. Psychedelics also gained attention, though MDMA approval for PTSD was deferred. Despite these innovations, mental health services remain under strain, with urgent need for more trained professionals and continued research funding.